19 terminated. 19 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Terminated 19 |
| Phase 2 | 4 | Terminated 4 |
Follow Hepatitis B: new trials by email Literature Review of Hepatitis B trials Research Report on Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 YS-HBV-002 - Chronic Hepatitis B | Phase 1 | Terminated | Yisheng Biopharma (Singapore) Pte. Ltd. | 16 | 2024-07-01 | 2025-02-24 |
| A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection 162, Placebo - Chronic Hepatitis B Virus Infection | Phase 1 | Terminated | Yangshengtang Co., Ltd | 1 | 2024-06-03 | 2024-07-16 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection RO7565020, Placebo, Nucleos(t)ide analogue (NUC) treatment - Chronic Hepatitis B | Phase 1 | Terminated | Hoffmann-La Roche | 60 | 2023-04-28 | 2026-01-22 |
| A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects ALG-125755, Placebo - Chronic Hepatitis B | Phase 1 | Terminated | Aligos Therapeutics | 57 | 2022-10-07 | 2024-03-15 |
| A Single and Multiple Ascending Dose Study of JNJ-64457744 JNJ-64457744, Placebo, Tenofovir Disoproxil Fumarate (TDF) - Healthy, Hepatitis B, Chronic | Phase 1 | Terminated | Janssen Research & Development, LLC | 60 | 2022-07-04 | 2025-02-03 |
| Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection GSK3965193, Placebo to match GSK3965193, Bepirovirsen - Hepatitis B | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 74 | 2022-04-14 | 2026-10-14 |
| Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects ATI-2173 50 mg - Chronic Hepatitis b | Phase 1 | Terminated | Antios Therapeutics, Inc | 37 | 2022-03-29 | 2022-11-18 |
| A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects ALG-020572, Placebo - Chronic Hepatitis B | Phase 1 | Terminated | Aligos Therapeutics | 40 | 2021-09-25 | 2023-04-25 |
| A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. EDP-721, Placebo (Part 1), EDP-721 (Part 2) - Chronic Hepatitis B Virus Infection | Phase 1 | Terminated | Enanta Pharmaceuticals, Inc | 26 | 2021-08-02 | 2022-02-14 |
| Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of â… Phase of Study HEC121120 tablets, HEC121120 placebo tablets, entecavir tablets - Hepatitis B, Chronic | Phase 1 / Phase 2 | Terminated | Sunshine Lake Pharma Co., Ltd. | 52 | 2020-10-09 | 2024-06-24 |
| A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects ALG-010133, Placebo - Chronic Hepatitis B | Phase 1 | Terminated | Aligos Therapeutics | 103 | 2020-08-17 | 2022-03-15 |
| Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation - Hepatitis B, Chronic | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 236 | 2019-03-28 | 2026-02-20 |
| A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection RO7239958, Placebo - Hepatitis B Virus Infection | Phase 1 | Terminated | Hoffmann-La Roche | 55 | 2018-12-14 | 2021-05-11 |
| Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers AL-3778, Entecavir, Tenofovir disoproxil fumarate - Hepatitis B, Chronic Hepatitis B | Phase 1 | Terminated | Alios Biopharma Inc. | 54 | 2017-01-31 | 2017-10-16 |
| A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection ALN-HBV, Sterile Normal Saline (0.9% NaCl) - Hepatitis B, Chronic Hepatitis B | Phase 1 | Terminated | Alnylam Pharmaceuticals | 24 | 2016-06-24 | 2018-09-24 |
| A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) ARC-521 Injection, Placebo, antihistamine - Hepatitis B | Phase 1 | Terminated | Arrowhead Pharmaceuticals | 47 | 2016-06-01 | 2026-01-12 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients Matching Placebo, RO7020322 - Hepatitis B, Chronic | Phase 1 | Terminated | Hoffmann-La Roche | 49 | 2015-11-28 | 2017-05-25 |
| Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B Antiviral Therapy (tenofovir or entecavir), Birinapant, Placebo (for birinapant) - Hepatitis B | Phase 1 | Terminated | TetraLogic Pharmaceuticals | 7 | 2014-11-01 | 2016-02-05 |
| Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects albinterferon alfa-2b, Pegasys® - Chronic Hepatitis B | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 141 | 2009-07-01 | 2011-01-06 |
Hepatitis B, Chronic (16) · Bronchiolitis Obliterans Syndrome (1)
Blood-Borne Infections (19) · Communicable Diseases (19) · DNA Virus Infections (19) · Digestive System Diseases (19) · Hepadnaviridae Infections (19) · Hepatitis (19) · Hepatitis, Viral, Human (19) · Infections (19) · Liver Diseases (19) · Virus Diseases (19) · Chronic Disease (16) · Disease Attributes (16) · Hepatitis, Chronic (16) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16)
entecavir (5) · Tenofovir (4) · Acetaminophen (1) · Dosage Forms (1) · Histamine Antagonists (1) · NVR 3-778 (1) · Nucleobindins (1) · Therapeutics (1) · albinterferon alfa-2b (1) · birinapant (1) · peginterferon alfa-2a (1) · tenofovir alafenamide (1)
Aligos Therapeutics (3) · Hoffmann-La Roche (3) · GlaxoSmithKline (2) · Alios Biopharma Inc. (1) · Alnylam Pharmaceuticals (1) · Antios Therapeutics, Inc (1) · Arrowhead Pharmaceuticals (1) · Enanta Pharmaceuticals, Inc (1) · Janssen Research & Development, LLC (1) · Novartis Pharmaceuticals (1) · Sunshine Lake Pharma Co., Ltd. (1) · TetraLogic Pharmaceuticals (1) · Yangshengtang Co., Ltd (1) · Yisheng Biopharma (Singapore) Pte. Ltd. (1)
New Zealand (11) · Hong Kong (7) · United Kingdom (6) · South Korea (5) · Taiwan (5) · Thailand (4) · Australia (3) · China (3) · Poland (3) · Bulgaria (2) · France (2) · Moldova (2) · Spain (2) · United States (2) · Belgium (1)
Ike Minerva, MD (1) · Stephen Huang, MD (1) · William D Kennedy, MD (1)
PMID 24995515, PMID 37290591, PMID 40118118, PMID 41186228
2017 (1), 2018 (1), 2023 (1)